ClinicalTrials.gg

Program

pevifoscorvir sodium

Also written as “ALG-000184” and “Pevifoscorvir Sodium (ALG-000184)”.

Its studies are mostly in Hepatitis B, Chronic, led by Aligos Therapeutics.

Furthest: phase 2, since Apr 22, 20255 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aligos Therapeutics52 open or runningphase 2since Apr 22, 2025Aug 28, 2020Mar 2027phase 2 · NCT06963710

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2020First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT04536337 · 165 enrolled · Australia, China, Hong Kong and more
  2. Sep 25, 2024Phase 1 study in Healthy VolunteerNCT06672900 · 24 enrolled · United States
  3. Apr 22, 2025Phase 2 study in Hepatitis B, ChronicNCT06963710 · 200 enrolled · United States, Bulgaria, Canada and more
  4. Dec 15, 20252 phase 1 studiesNCT07342881, NCT07342868

Ahead

  1. Mar 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT06963710

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07342881Hepatitis B, Chronic · United States1CompletedJul 29, 202612
NCT07342868Chronic Hepatitis B Infections · United States1CompletedAug 19, 202620
NCT06963710Hepatitis B, Chronic · United States, Bulgaria, Canada and more2Active, not recruitingMar 2027200
NCT06672900Healthy Volunteer · United States1Active, not recruitingJul 7, 202524
NCT04536337Hepatitis B, Chronic · Australia, China, Hong Kong and more1CompletedJun 16, 2025165

How it is read

Names in the registry

  • “ALG-000184”, 3 entries
  • “Pevifoscorvir Sodium (ALG-000184)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.